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Background
There is a growing interest in the association between schizophrenia and the activation of inflammatory system with signs of acute phase (AP) response. Majority of such studies had focused on C-reactive protein (CRP). The aims of the present study were (i) to examine the gene expression profiles of other acute phase proteins (APP), namely haptoglobin (HP), alpha-1 antitrypsin (A1T), and alpha-2 macroglobulin (A2M) in patients with first episode psychosis (FEP) over a period of three months and (ii) to explore the association between APP levels and severity of symptoms.
Methods
In this study, HP, A1T and A2M gene expression levels from whole blood were measured at recruitment, 1-and 3-month follow-up visits using quantitative PCR (qPCR) in 43 patients with FEP and in 57 healthy controls. Diagnoses was ascertained on the Structured Clinical Interview for DSM-IV-TR. Severity of symptoms in patients was assessed on the Positive and Negative Syndrome Scale (PANSS) and a previously validated 5-factor PANSS structure was applied in the subsequent analyses.
Results
The FEP sample comprised of 28 (65.1%) individuals with schizophrenia, 12 (27.9%) with schizophreniform disorder and 3 (7%) with schizoaffective disorder. HP gene expression level was noted to be significantly higher in patients than controls at all three time points: recruitment (P=0.049), 1-month follow up (P=0.002) and 3-month follow up (P=0.005). PANSS positive, depression, and excitement symptom factors showed significant associations with HP (P=0.002), A1T (P=0.016) and A2M (P=0.034), respectively. These findings remained significant after controlling for age, gender, smoking status and accumulated chlorpromazine dosage.
Conclusion
The current study provides information on HP, A1T and A2M gene expression profiles in FEP patients and their associations with psychopathology. This provides support for the hypothesis
Introduction
Macrophages and T-lymphocytes were hypothesised to be activated in psychosis with an accompanying acute phase (AP) response (Smith and Maes, 1995) . An acute phase response is characterised by: (1) an increase in serum levels of positive acute phase proteins (APP), examples of positive APPs are C-reactive protein (CRP), haptoglobin (HP), alpha-1 antitrypsin (A1T), alpha-2 macroglobulin (A2M), ceruloplasmin and complement factors; (2) a decrease in serum levels of negative APPs such as albumin, transferrin, transthyretin, transcortin and insulin like growth factor I (Maes et al., 1997b) .
The functions of most APPs and their interactions have not been fully understood. Positive APPs are thought to have general functions in opsonization and trapping of micro-organisms and their products, in activating complement, in binding cellular remnants like nuclear fractions, in neutralizing enzymes, scavenging free haemoglobin and radicals and in modulating the host's immune system (Gruys et al., 2005) , From the limited literature and in clinical practice, HP is used to screen for and monitor intravascular haemolytic anaemia. It binds strongly to haemoglobin, preventing iron loss and renal damage. HP also has antibacterial property and binds to receptors on cell membranes of leukocytes (Wassell, 2000) . A1T, which is considered to be the most prominent serpin, is involved in minimizing damage caused by activated neutrophil granulocytes and elastase which breaks down connective tissue fibre, elastin (Gettins, 2002) . A2M, a protease inhibitor, was studied to be able to bind to protease involved in coagulation, fibrinolysis, inflammation and proteases from pathogens. In animal models, A2M was observed to augment the phagocytosis of sheep red blood cells by mouse macrophages (Sottrup-Jensen, 1989 ).
There have been reports on the alterations of APP levels in various mental disorders; for instance, in acute psychosis, schizophrenia, depression, bipolar disorders, and mania (Maes et al., 1997a; Morera et al., 2006; Wan et al., 2007; Wong et al., 1996) . CRP is used in clinical practice as a non-specific marker of inflammation, therefore its elevated protein levels has received attention in psychosis (Dickerson et al., 2007; Fan et al., 2007; Fawzi et al., 2011; Johnsen et al., 2016; Lin et al., 2013; Maes et al., 1997a; Wong et al., 1996) . However, studies on other APPs were limited, inconsistent and sometimes lacking a comparison group. Studies have also reported inconsistent changes in other APPs such as HP, A1T, A2M, ceruloplasmin, complement C3, C4, and transferrin protein levels in different stages of schizophrenia, and in acute psychosis (Bock et al., 1971; Morera et al., 2006; Seal and Eist, 1966; Wan et al., 2007; Wong et al., 1996; Yang et al., 2006 (Dickerson et al., 2007; Fan et al., 2007; Fernandes et al., 2016; Johnsen et al., 2016) . Up to now, there is only one report on significant associations between other APPs (C3, C4 and ceruloplasmin) and symptoms -negative and general psychopathology -in patients with schizophrenia (Wan et al., 2007) . While these reports had described changes in plasma and serum levels of APPs in psychosis, transcriptomic data on these APPs was lacking. The transcriptomic data is important for the understanding of functional elements of genome, unfolding of molecular constituents of cells and tissues, as well as to study the development of disorder (Wang et al., 2009) . We had previously reported peripheral blood gene expression profiles of patients with FEP which revealed an up-regulation of HP gene expression (Lee et al., 2012) . Therefore, the objectives of the current study were: (1) to extend the findings of differential HP gene expression levels, along with A1T and A2M in FEP to a larger sample group over a period of 3 months, and (2) to explore the associations between HP, A1T and A2M gene expression levels and severity of symptoms.
Methods and Materials
Study sample
The current case control study was conducted at the institute of Mental Health, Singapore.
Cases were individuals diagnosed with FEP who have had less than 4 weeks of antipsychotic treatment. Only individuals with a diagnosis of schizophrenia, schizophreniform or schizoaffective disorder at 3-month follow-up visit were recruited for this study. Three-month of follow up was chosen as this period should be adequate to identify antipsychotic response. Controls were healthy individuals with no history of mental illness, substance use, intellectual disability and neurological disorders. Controls were matched to cases for age, ethnicity and gender. Sociodemographic data such as age, gender, ethnicity and smoking status were obtained from all study participants. Prescription information for antipsychotics was obtained from medical records.
Antipsychotic doses were converted into chlorpromazine (CPZ) equivalents and aggregated amount from initiation of pharmacotherapy to recruitment was computed (accumulated CPZ in mg). Ethics approval for the study was provided by the Domain Specific Review Board of the National Healthcare Group, Singapore.
Assessments
All participants were assessed using the Structured Clinical Interview for DSM-IV-TR (SCID-I). Clinical symptoms were assessed on the Positive and Negative Syndrome Scale (PANSS) by trained raters with established inter-rater reliability at > 0.8. Controls were assessed on the SCID-I to determine history of mental illness at recruitment.
Sample collection and RNA extraction
A sample of venous whole blood was collected from all subjects at recruitment, 1-and 3-month follow-up visits into Tempus TM Blood RNA Tube (ThermoFisher Scientific, Foster City, CA, USA), and stored at -80°C. Total RNA from all three time points was then converted to complementary DNA (cDNA) using iScript™ Reverse Transcription Supermix (Bio-Rad, Hercules, California, USA). HP, A1T
and A2M gene sequences were obtained from NCBI gene bank and primers specific for respective genes designed using PrimerQuest (Integrated DNA Technologies, Coralville, Iowa, USA). GADPH was used as a reference for relative quantification of APP genes using ∆∆Ct method. All samples were ran in triplicates; each reaction consisting 100ng cDNA, 10µM of forward and reverse primers and 2X iQ™ SYBR® Green Supermix (Bio-Rad, Hercules, California, USA). All reactions were programmed to run at a hold of 50°C for 2 minutes, denaturation of 95°C for 3 minutes, 40 cycles of denaturation at 95°C for 10 seconds, annealing at 65°C for 20 seconds, and elongation at 72°C for 30 seconds, followed by a final elongation at 72°C for 1 minute on CFX96 Touch™ Real-Time PCR Detection System (Bio-Rad, Hercules, California, USA). Melting curves and cycle threshold (CT) values were generated upon completion of qPCR cycle. Each sample was assayed in triplicates and each target gene (HP, A1T, and A2M) was normalized to the expression of a reference gene, glyceraldehyde 3-phosphate dehydrogenase (GAPDH). A second normalization against inter-run calibrator was performed to remove run-to-run difference. Relative quantitation using the 2 ∆∆ -Ct formula which derives fold change corresponding to gene expression was performed to analyse the results obtained from all the real-time PCR runs.
Statistical analyses
Categorical and continuous data were analysed using chi-squared test and Mann-Whitney U test respectively to compare the characteristics of patients and healthy controls. Linear regression model was used to investigate the association between APP gene expression levels and symptom severity using a PANSS 5-factor model that was previously validated in our local dataset (Jiang et al., 2013) . The final linear regression model included age, gender, smoking status and accumulated CPZ which were studied to be associated with changes in APP levels (Dietrich et al., 2007; Johnsen et al., 2016; Lakoski et al., 2006; Maes et al., 1997a) . Data was analysed on SPSS Statistics version 23 (IBM Co., Armonk, NY, USA).
Results
Clinical characteristics
A total of 43 cases with FEP (28 with schizophrenia, 12 with schizophreniform disorder and 3 with schizoaffective disorder) and 57 healthy controls were recruited into the study. There were no significant differences in gender, ethnicity, smoking status, age, BMI between cases and controls at recruitment. Characteristics of both case and control groups are summarized in Table   1 . Tables 3, 4 and 5.
APP gene expression profiles
Discussion
To our knowledge, this is the first study to examine HP, A1T and A2M gene expression levels longitudinally in individuals with FEP and in healthy controls. It is also the first study to examine the relationship between gene expression levels of HP, A1T and A2M and the psychopathological profiles of FEP. The major findings of this study are; (1) significant and persistent upregulation of HP gene expression levels can be observed in patients with FEP, and (2) significant associations between APPs and symptom severity after controlling for age, gender, smoking status and accumulated CPZ.
Upregulated HP gene expression levels in patients are consistent with earlier reports on elevated protein levels (Bock et al., 1971; Maes et al., 1997a; Seal and Eist, 1966; Wan et al., 2007; Yang et al., 2006) . In contrary to reported studies on elevated or unchanged A1T serum levels in patients with schizophrenia than controls, the current study observed a lower A1T gene expression level in the patient group at 1-month follow-up visit when compared to control group (Bock et al., 1971; Wan et al., 2007; Wong et al., 1996; Yang et al., 2006) . In contrast to published data on significantly higher levels of A2M in patients with schizophrenia at recruitment, the current study noted higher serum levels of A2M gene expression in patient group, but the significance was only reached at 3-month follow up visit (Bock et al., 1971; Wong et al., 1996) .
There can be several explanations for the observed AP response. Stress, leading to alterations in hormonal levels may cause changes in the hepatic syntheses of these APPs (Maes et al., 1997a; Wan et al., 2007; Wong et al., 1996) . In a chronic mildly stressed rat model, an elevated plasma HP level was observed (Maes et al., 1997a) . Thus, the elevated HP gene expression level observed in the current study might be due to the psychological stress which accompanies psychosis. Another plausible explanation for the increased APP level is infections (Wong et al., 1996) . It was proposed that prenatal infection leads to the activation of the expecting mother's immune system, thus releasing cytokines (Horváth and Mirnics, 2014) . This spike in maternal cytokine levels lead to the flood of cytokines and immune-response proteins in the developing foetal brain via diffusion (Horváth and Mirnics, 2014) . In the absence of genetic risk to schizophrenia, the intrinsic compensatory mechanism is able to normalise quickly to resume development with minimal disruption (Horváth and Mirnics, 2014) . For foetuses with schizophrenia-predisposing genetic material, the foetal meninges and blood vessels become hyper-responsive and this inflammation response becomes chronic, interfering with post-natal neuronal connectivity and synapse pruning (Horváth and Mirnics, 2014) . This prolonged inflammatory response may drain the brain's innate compensatory mechanism, rousing the symptoms of psychosis to manifest (Horváth and Mirnics, 2014 (Wong et al., 1996) . Pro-inflammatory cytokines such as TNF-α, IL-1 and IL-6 are involved in the activation of hepatocytic receptors, thus initiating the synthesis of acute phase proteins (Gruys et al., 2005) . While TNF-α and IL-1 initiates muscle catabolism and glucagoninduced hyperglycaemia and amino acid uptake by liver, IL-6 is the major mediator for hepatic secretion of most APPs (Gruys et al., 2005) . A recent review reported a consistent increase in the abovementioned cytokines in FEP studies (Zajkowska and Mondelli, 2014) . The present study finding of upregulated HP gene expression may be due to the increase in pro-inflammatory cytokines.
The literature on relationship between APP and symptom severity in schizophrenia is limited and focused mainly on CRP (Dickerson et al., 2007; Fan et al., 2007; Johnsen et al., 2016) . While Dickerson et al. and Johnsen et al. reported no association between CRP and symptom severity, Fan et al. observed a significant associations between CRP and PANSS total, negative symptom and general psychopathology subscale scores (Dickerson et al., 2007; Fan et al., 2007; Johnsen et al., 2016) . Although the underlying mechanisms behind inflammation and schizophrenia remains unclear, it was also proposed that long term inflammation may damage micro-vascular system in the brain, thus breaching the homeostasis within the brain, leading to development of psychosis (Fan et al., 2007) . Furthermore, imaging studies showed deficient blood flow in the frontal and temporal lobes in schizophrenia and this drop in blood flow was associated with negative symptoms (Fan et al., 2007) . Therefore, the current finding is of interest in light of studies reporting associations between APPs and symptom severity in schizophrenia.
Beside the small sample size, there are several limitations in this study. First, patients recruited in this study were on antipsychotics and psychotropics which might interfere with APP levels (Fan et al., 2007; Maes et al., 1997a; McNamara et al., 2011; Miller et al., 2011) . Though capped at no more than 4 weeks, this exposure was of varying duration. Furthermore, the naturalistic study design meant antipsychotic treatments were not restricted in type or dosing.
Medical conditions associated to inflammation such as metabolic disorders and asthma, and antiinflammatory medications may have an influence on the APP gene expression levels. Although we attempted to adjust for accumulated antipsychotic exposure in our analyses, we cannot completely control for the confounding effects of these medical conditions and/or treatments on APP expression. Second, there is a difference in the timing and magnitude of response among different APPs. For example, CRP and serum amyloid can be induced by 1000-fold while Hp and fibrinogen proteins increased by around 50% after inflammatory stimulus (Gabay and Kushner, 1999) . CRP protein level starts to rise within the first 4-6 hours after inflammatory stimulus and reaches its peak level in blood within the second or third day while fibrinogen increases only 3-fold but peaks over a week after initial stimulation (Adelstein Stephen, 2014) . The blood specimen collected in the study could be at a phase of normalization of APP levels after initial elevation.
Third, because of the cross-sectional design of this study, the causal association between APP and symptoms remained uncertain.
Conclusion
In summary, our observations of altered gene expression levels of APPs and their associations with symptom severity in patients with FEP lend support to the hypothesis that inflammatory responses are related to the pathophysiology and development of schizophrenia.
This should encourage future studies on APP or other inflammatory markers to aid in understanding the relationship between inflammation and schizophrenia. Tables   Table 1 Characteristics of study samples at recruitment (baseline) Table 2 APP gene expression levels at recruitment (baseline), 1-and 3-month follow-up visits Table 3 Association between HP gene expression and symptoms factors Table 4 Association between A1T gene expression and symptoms factors Table 5 Association between A2M gene expression and symptoms factors
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